{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:49:41Z","timestamp":1787028581631,"version":"build-2736575974"},"reference-count":42,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","award":["E-26\/210.585\/2024"],"award-info":[{"award-number":["E-26\/210.585\/2024"]}],"id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]},{"award":["E-26\/210.585\/2024"],"award-info":[{"award-number":["E-26\/210.585\/2024"]}],"id":[{"id":"https:\/\/ror.org\/03kk0s825","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["309649\/2022-6"],"award-info":[{"award-number":["309649\/2022-6"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"award":["309649\/2022-6"],"award-info":[{"award-number":["309649\/2022-6"]}],"id":[{"id":"https:\/\/ror.org\/03swz6y49","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024786","name":"Oswaldo Cruz Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100024786","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Direct-acting antivirals (DAAs) have revolutionized hepatitis C virus (HCV) therapy, yet resistance-associated substitutions (RASs) remain a concern in specific clinical contexts. Here, we present a database-derived global overview of HCV RASs by analyzing 19,449 publicly available sequences across multiple genotypes and subtypes, encompassing both untreated and previously treated infections, in the NS3, NS5A, and NS5B genomic regions. We demonstrate a markedly heterogeneous distribution of RASs shaped by viral genotype, geographic origin, and treatment era. Importantly, RASs against pan-genotypic NS3 protease inhibitors (glecaprevir and voxilaprevir) were rare (generally &lt;1% across genotypes). In contrast, NS5A inhibitors showed greater vulnerability, with the Y93H substitution detected at notable frequencies in major genotypes (3.2\u20137.0%) and near-universal resistance-associated substitutions (e.g., 100% Q30S) observed in the rare genotype 8. The NS5B nucleotide analogue sofosbuvir retained a high genetic barrier, with the canonical S282T substitution detected only sporadically (2.1% of genotype 4 sequences). At the population level, geographic heterogeneity was evident, with higher RAS frequencies observed in specific regions, alongside pronounced data gaps in high-prevalence areas of Africa. Temporal analyses revealed an increase in NS3 and NS5A RASs following the introduction of first-generation DAAs, with NS5A substitutions persisting into the current interferon-free era, whereas NS5B resistance remained consistently rare across all treatment periods. Together, these findings provide a global, population-level overview of resistance-associated HCV diversity and reinforce the durability of high-barrier regimens while highlighting persistent genotype-specific vulnerabilities with implications for antiviral resistance surveillance and HCV elimination efforts.<\/jats:p>","DOI":"10.3390\/ijms27115068","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T18:08:07Z","timestamp":1780510087000},"page":"5068","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Database-Derived Global Overview of HCV Resistance-Associated Substitutions: Characterizing Genotypic, Regional, and Temporal Heterogeneity"],"prefix":"10.3390","volume":"27","author":[{"given":"Gabriela Tavares Marinho","family":"Nunes","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Virology and Parasitology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2837-4402","authenticated-orcid":false,"given":"Tha\u00eds Barbosa Ferreira","family":"Sant\u2019Anna","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Virology and Parasitology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9037-1304","authenticated-orcid":false,"given":"Natalia Motta","family":"de Araujo","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Virology and Parasitology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.2523562","article-title":"Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome","volume":"244","author":"Choo","year":"1989","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Manns, M.P., Buti, M., Gane, E., Pawlotsky, J.M., Razavi, H., Terrault, N., and Younossi, Z. (2017). Hepatitis C virus infection. Nat. Rev. Dis. Primers, 3.","DOI":"10.1038\/nrdp.2017.6"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.jhep.2021.03.004","article-title":"Treatment failure with DAA therapy: Importance of resistance","volume":"74","author":"Sarrazin","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrmicro1645","article-title":"Replication of hepatitis C virus","volume":"5","author":"Moradpour","year":"2007","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_5","unstructured":"ICTV (2025, October 03). Flaviviridae: Hepacivirus C Classification. Available online: https:\/\/ictv.global\/sg_wiki\/flaviviridae\/hepacivirus."},{"key":"ref_6","unstructured":"The World Health Organization (WHO) (2025, October 03). Fact Sheets. Hepatitis C. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Di Marco, L., Cannova, S., Ferrigno, E., Landro, G., Nonni, R., Mantia, C., Cartabellotta, F., Calvaruso, V., and Di Marco, V. (2025). A Comprehensive Review of Antiviral Therapy for Hepatitis C: The Long Journey from Interferon to Pan-Genotypic Direct-Acting Antivirals (DAAs). Viruses, 17.","DOI":"10.3390\/v17020163"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_9","unstructured":"Bhattacharya, D., Aronsohn, A., Price, J., Lo Re, V., and Panel, A.-I.H.G. (2023). Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin. Infect. Dis., ciad319."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"EASL (2020). EASL recommendations on treatment of hepatitis C: Final update of the series. J. Hepatol., 73, 1170\u20131218. Erratum in J. Hepatol. 2023, 78, 452. https:\/\/doi.org\/10.1016\/j.jhep.2022.10.006.","DOI":"10.1016\/j.jhep.2022.10.006"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/hep.27934","article-title":"Hepatitis C virus drug resistance-associated substitutions: State of the art summary","volume":"62","author":"Lontok","year":"2015","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jhep.2022.08.016","article-title":"Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure","volume":"78","author":"Dietz","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3851\/IMP3181","article-title":"Long-term persistence of HCV NS5A resistance-associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir","volume":"23","author":"Wyles","year":"2018","journal-title":"Antivir. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Schnell, G., Krishnan, P., Tripathi, R., Beyer, J., Reisch, T., Irvin, M., Dekhtyar, T., Lu, L., Ng, T.I., and Xie, W. (2018). Hepatitis C virus genetic diversity by geographic region within genotype 1-6 subtypes among patients treated with glecaprevir and pibrentasvir. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0205186"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jhep.2009.05.016","article-title":"Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C","volume":"51","author":"Bochud","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection","volume":"373","author":"Foster","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1002\/hep.29837","article-title":"Resistance analysis of genotype 3 hepatitis C virus indicates subtypes inherently resistant to nonstructural protein 5A inhibitors","volume":"69","author":"Smith","year":"2019","journal-title":"Hepatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/hep4.1060","article-title":"The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment","volume":"1","author":"Gane","year":"2017","journal-title":"Hepatol. Commun."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1093\/cid\/ciu697","article-title":"Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials","volume":"59","author":"Svarovskaia","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_20","unstructured":"AASLD\u2013IDSA (2025, October 06). HCV Resistance Primer. Available online: https:\/\/www.hcvguidelines.org\/evaluate\/resistance."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/infdis\/jiy401","article-title":"Identification of a Novel Hepatitis C Virus Genotype from Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes","volume":"218","author":"Borgia","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_23","unstructured":"C U.S. Food and Drug Administration (2025, October 03). Zepatier (Elbasvir and Grazoprevir) Tablets, for Oral Use [Prescribing Information], Available online: https:\/\/www.fda.gov\/drugsatfda."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Simicic, P., Slovic, A., Radmanic, L., Vince, A., and Zidovec Lepej, S. (2022). Molecular Epidemiology and Baseline Resistance of Hepatitis C Virus to Direct Acting Antivirals in Croatia. Pathogens, 11.","DOI":"10.3390\/pathogens11070808"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Krishnan, P., Pilot-Matias, T., Schnell, G., Tripathi, R., Ng, T.I., Reisch, T., Beyer, J., Dekhtyar, T., Irvin, M., and Xie, W. (2018). Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.01249-18"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Sulbaran, M.Z., Di Lello, F.A., Sulbaran, Y., Cosson, C., Loureiro, C.L., Rangel, H.R., Cantaloube, J.F., Campos, R.H., Moratorio, G., and Cristina, J. (2010). Genetic history of hepatitis C virus in Venezuela: High diversity and long time of evolution of HCV genotype 2. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0014315"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ijid.2021.12.320","article-title":"Frequency distribution of HCV resistance-associated variants in infected patients treated with direct-acting antivirals","volume":"115","author":"Cabral","year":"2022","journal-title":"Int. J. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.clinre.2019.02.009","article-title":"Prevalence of baseline NS3 resistance-associated substitutions (RASs) on treatment with protease inhibitors in patients infected with HCV genotype 1","volume":"43","author":"Costa","year":"2019","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2147\/IDR.S247071","article-title":"Prevalence and Pattern of Resistance in NS5A\/NS5B in Hepatitis C Chronic Patients Genotype 3 Examined at a Public Health Laboratory in the State of Sao Paulo, Brazil","volume":"14","author":"Lemos","year":"2021","journal-title":"Infect. Drug Resist."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Lopez-Osorio, M.C., Usme-Ciro, J.A., Martinez, J.W., Pelaez-Carvajal, D., Hernandez, J., Hoyos, S., Restrepo, J.C., and Navas, M.C. (2022). Genetic diversity of hepatitis C virus and resistance associated substitutions to direct-acting antiviral treatment in Colombia. Virus Res., 318.","DOI":"10.1016\/j.virusres.2022.198847"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Malta, F., Gaspareto, K.V., Lisboa-Neto, G., Carrilho, F.J., Mendes-Correa, M.C., and Pinho, J.R.R. (2017). Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil. BMC Infect. Dis., 17.","DOI":"10.1186\/s12879-017-2817-7"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1002\/jmv.25536","article-title":"Hepatitis C virus genotype 1 infection: Prevalence of NS5A and NS5B resistance-associated substitutions in naive patients from Argentina","volume":"91","author":"Martinez","year":"2019","journal-title":"J. Med. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Bittar, C., Jardim, A.C., Yamasaki, L.H., Carareto, C.M., Pinho, J.R., Lemey, P., de Carvalho-Mello, I.M., and Rahal, P. (2013). On hepatitis C virus evolution: The interaction between virus and host towards treatment outcome. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0062393"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.aohep.2019.08.001","article-title":"Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil","volume":"18","author":"Lobato","year":"2019","journal-title":"Ann. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Rodrigues, J.P.V., Campos, G.R.F., Bittar, C., Martinelli, A.L.C., Campos, M.S.A., Pereira, L.R.L., Rahal, P., and Souza, F.F. (2022). Selection dynamics of HCV genotype 3 resistance-associated substitutions under direct-acting antiviral therapy pressure. Braz. J. Infect. Dis., 26.","DOI":"10.1016\/j.bjid.2022.102717"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/nature04082","article-title":"Mechanism of action of interferon and ribavirin in treatment of hepatitis C","volume":"436","author":"Feld","year":"2005","journal-title":"Nature"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jhep.2011.01.011","article-title":"Hepatitis C virus resistance to protease inhibitors","volume":"55","author":"Halfon","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/03009734.2018.1441928","article-title":"The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: Experience from a small Swedish cohort","volume":"123","author":"Kjellin","year":"2018","journal-title":"Ups. J. Med. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","article-title":"Resistance to direct antiviral agents in patients with hepatitis C virus infection","volume":"138","author":"Sarrazin","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_40","first-page":"103","article-title":"Understanding Hepatitis C Virus Drug Resistance: Clinical Implications for Current and Future Regimens","volume":"25","author":"Wyles","year":"2017","journal-title":"Top. Antivir. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drup.2018.01.004","article-title":"Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018","volume":"37","author":"Sorbo","year":"2018","journal-title":"Drug Resist. Updat."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1093\/molbev\/msab120","article-title":"MEGA11: Molecular Evolutionary Genetics Analysis Version 11","volume":"38","author":"Tamura","year":"2021","journal-title":"Mol. Biol. Evol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/11\/5068\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:09:51Z","timestamp":1780636191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/11\/5068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":42,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["ijms27115068"],"URL":"https:\/\/doi.org\/10.3390\/ijms27115068","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]}}}